Wilkinson S E, Hallam T J
Roche Research Centre, Herts, UK.
Trends Pharmacol Sci. 1994 Feb;15(2):53-7. doi: 10.1016/0165-6147(94)90110-4.
Evidence has emerged over the past decade to suggest that protein kinase C (PKC) is a widespread family of kinases responsible for many diverse and critical cellular functions. With the development of selective agents to activate or inhibit the individual PKC isoenzymes, it is now apparent that much of the literature that implicated PKC in many cellular functions needs to be appraised. In this article, Sandra Wilkinson and Trevor Hallam discuss the problems of the existing methods and the recent evidence that suggests that PKC isotypes are necessary for some, but not all, of those cellular responses where PKC had been thought to play an important role. Selective inhibitors of PKC isoenzymes may have potential for therapeutic use in auto-immune diseases, transplant rejection and oncology.
在过去十年中,有证据表明蛋白激酶C(PKC)是一个广泛存在的激酶家族,负责许多不同且关键的细胞功能。随着用于激活或抑制单个PKC同工酶的选择性药物的开发,现在很明显,许多将PKC与多种细胞功能联系起来的文献需要重新评估。在本文中,桑德拉·威尔金森和特雷弗·哈勒姆讨论了现有方法存在的问题以及最近的证据,这些证据表明PKC同工型对于某些(但不是所有)曾被认为PKC在其中发挥重要作用的细胞反应是必要的。PKC同工酶的选择性抑制剂在自身免疫性疾病、移植排斥和肿瘤学治疗中可能具有潜在用途。